Ikarian Capital, LLC Relmada Therapeutics, Inc. Put Options Transaction History
Ikarian Capital, LLC
- $640 Million
- Q3 2025
Put Options
2 transactions
Others Institutions Holding RLMD
# of Institutions
53Shares Held
6.25MCall Options Held
66KPut Options Held
0-
Driehaus Capital Management LLC Chicago, IL740KShares$2.92 Million0.01% of portfolio
-
Boothbay Fund Management, LLC New York, NY693KShares$2.74 Million0.02% of portfolio
-
Acadian Asset Management LLC Boston, MA583KShares$2.3 Million0.0% of portfolio
-
Black Rock Inc. New York, NY573KShares$2.26 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA419KShares$1.65 Million0.0% of portfolio
About RELMADA THERAPEUTICS, INC.
- Ticker RLMD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,608,500
- Market Cap $113M
- Description
- Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...